Market Overview

Invitae Responds Being Names as Defendant in Myriad Genetics Lawsuit

Share:

Invitae Corporation today announced that
it plans to defend its right to provide naturally occurring genetic
information and services to physicians for their cancer patients through

Invitae Corporation today announced that
it plans to defend its right to provide naturally occurring genetic
information and services to physicians for their cancer patients through
its genetic testing services. Invitae has been named a defendant in a
lawsuit filed by Myriad Genetics (NASDAQ: MYGN) regarding Invitae's BRCA and
MUTYH genetic tests. Invitae disagrees with the allegations of the
lawsuit and plans to vigorously defend itself against the lawsuit, which
it believes has no merit.

Earlier this year, the Supreme Court ruled that naturally occurring DNA
and the information it encodes cannot be patented (Assn'n for Molecular
Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 [2013]) and thus
ushered in a

See full press release

Posted-In: News Guidance Contracts Legal Management Global

 

Related Articles (MYGN)

View Comments and Join the Discussion!